REGISTERED NUMBER: 10083748 (England and Wales)

LONDON HEART CLINIC LIMITED

Financial Statements for the Year Ended 31 March 2024

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

3

DIRECTOR:

Jaspal Singh Kooner

REGISTERED OFFICE:

Unit 1 Manhattan Business Park, Westgate

Ealing, London, W5 1UP

W5 1UP

REGISTERED NUMBER:

10083748 (England and Wales)

AUDITORS:

DSJ Partners (UK) Limited

2nd Floor

1 Bell Street

London

NW1 5BY

FIXED ASSETS

Tangible assets

4

39,813

21,253

CURRENT ASSETS

Debtors

5

1,253,719

1,156,041

Cash in hand

414,691

570,189

1,668,410

1,726,230

CREDITORS

Amounts falling due within one year

6

(160,850

)

(147,118

)

NET CURRENT ASSETS

1,507,560

1,579,112

TOTAL ASSETS LESS CURRENT LIABILITIES

1,547,373

1,600,365

CAPITAL AND RESERVES

Called up share capital

1,000

1,000

Retained earnings

1,546,373

1,599,365

1,547,373

1,600,365

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 20 October 2025 and were signed by:

Jaspal Singh Kooner - Director

1.	STATUTORY INFORMATION

LONDON HEART CLINIC LIMITED is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going concern

The financial statements have been prepared on a going concern basis as the director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future and will be able to pay its debts as and when they fall due.

In order to assess the going concern assumption, the company has prepared and considered trading and cashflow forecasts for the period covering at least 12 months from the date of approval of these financial statements.

Having considered the information available to her to the date of signing the financial statements, the director is satisfied that the company remains a going concern.

Revenue

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Depreciation is provided on the following basis:

Fixtures and fittings - 25% straight-line method

Computer equipment - 25% straight-line method

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

Fixed assets impairment

Fixed assets are reviewed for impairment if events or changes in circumstances indicate that the carrying amount may not be recoverable or as otherwise required by relevant accounting standards.

Shortfalls between the carrying value of fixed assets and their recoverable amounts, being the higher of net realisable value and value in use, are recognised as impairments. All other impairment losses are recognised in the profit and loss account.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Financial instruments

The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102, in full, to all of its financial instruments.

Financial assets and financial liabilities are recognised when the company becomes a party to the contractual provisions of the instrument, and are offset only when the company currently has a legally enforceable right to set off the recognised amounts and intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Financial assets

Trade debtors

Trade debtors which are receivable within one year and which do not constitute a financing transaction are initially measured at the transaction price. Trade debtors are subsequently measured at amortised cost, being the transaction price less any amounts settled and any impairment losses.

Where the arrangement with a trade debtor constitutes a financing transaction, the debtor is initially and subsequently measured at the present value of future payments discounted at a market rate of interest for a similar debt instrument.

A provision for impairment of trade debtors is established when there is objective evidence that the amounts due will not be collected according to the original terms of the contract. Impairment losses are recognised in profit or loss for the excess of the carrying value of the trade debtor over the present value of the future cash flows discounted using the original effective interest rate. Subsequent reversals of an impairment loss that objectively relate to an event occurring after the impairment loss was recognised, are recognised immediately in profit or loss.

Financial liabilities and equity

Financial instruments are classified as liabilities and equity instruments according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Equity instruments

Financial instruments classified as equity instruments are recorded at the fair value of the cash or other resources received or receivable, net of direct costs of issuing the equity instruments.

Trade creditors

Trade creditors payable within one year that do not constitute a financing transaction are initially measured at the transaction price and subsequently measured at amortised cost, being the transaction price less any amounts settled.

Where the arrangement with a trade creditor constitutes a financing transaction, the creditor is initially and subsequently measured at the present value of future payments discounted at a market rate of interest for a similar instrument.

Derecognition of financial assets and liabilities

A financial asset is derecognised only when the contractual rights to cash flows expire or are settled, or substantially all the risks and rewards of ownership are transferred to another party, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party. A financial liability (or part thereof) is derecognised when the obligation specified in the contract is discharged, cancelled or expires.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was 10 (2023 - 9 ) .

4.	TANGIBLE FIXED ASSETS

Plant and

machinery

etc

£

COST

At 1 April 2023

53,335

Additions

42,267

At 31 March 2024

95,602

DEPRECIATION

At 1 April 2023

32,082

Charge for year

23,707

At 31 March 2024

55,789

NET BOOK VALUE

At 31 March 2024

39,813

At 31 March 2023

21,253

5.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2024

2023

£

£

Trade debtors

383,393

399,907

Amounts owed by group undertakings

856,965

741,084

Other debtors

13,361

15,050

1,253,719

1,156,041

6.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2024

2023

£

£

Trade creditors

96,298

38,939

Taxation and social security

31,888

5,988

Other creditors

32,664

102,191

160,850

147,118

7.	DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Bharat Kumar Dhanani (Senior Statutory Auditor)

for and on behalf of DSJ Partners (UK) Limited

8.	RELATED PARTY DISCLOSURES

Director, Mr J S Kooner has provided working capital loan to the company. This loan is interest free and repayable on demand. At the year end, balance owed to him was £2,635 (2023: £Nil).

The company has provided working capital loan to a fellow group company, Imperial Bio-Discovery Ltd. At the year end, amount receivable from them was £292,156 (2023: £246,110). The loan is non-interest bearing and repayable on demand.

The company has provided working capital loan to a fellow group company, Ealing Paces MRCP Limited. At the year end, amount receivable from them was £111,979 (2023: £100,785). The loan is non-interest bearing and repayable on demand.

The company has provided working capital loan to a fellow group company, Golden Manor Healthcare (Ealing) Limited. At the year end, amount receivable from them was £428,985 (2023: £389,340). The loan is non-interest bearing and repayable on demand.

The company has provided working capital loan from a fellow group company, JSK Private Practice Ltd. At the year end, amount receivable from them was £23,845 (2023: £720). The loan is non-interest bearing and repayable on demand.

9.	ULTIMATE CONTROLLING PARTY

The immediate parent company is 57 AG Limited which is registered in England and Wales and for which group financial statements are prepared. These are the smallest and largest group for which consolidated accounts including Golden Manor Healthcare (Ealing) Limited are prepared. Copies of the group financial statements are available from Companies House, Crown Way, Maindy, Cardiff, CF1 43UZ .

The company is under the control of Professor Jaspal Singh Kooner.